<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-053438</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Decrease in bactericidal activity of ciprofloxacin in Salmonella mutants generated following repeated exposure to various fluorquinolones</dc:title>
<dc:description xml:lang="en">Salmonella mutants with reduced fluoroquinolone susceptibility were generated in vitro following repeated exposure to subinhibitory concentrations    of the drugs and the alterations in the gyrA gene were characterized. Afterwards, the change in bactericidal activity exhibited    by ciprofloxacin against the resulting mutants was determined. A decrease in the bactericidal activity of ciprofloxacin was found in all the    mutants, but was more pronounced in mutants of nalidixic acid-resistant strains. This may help to explain the therapeutic failures sometimes    described when fluoroquinolones are used in the treatment of these strains. In addition, our model evaluates the first interactions produced    between the microorganism and the antibiotics, and demonstrates that the loss of bactericidal activity of ciprofloxacin occurs following exposure    to all of the fluoroquinolones tested</dc:description>
<dc:creator>Cebrián, L</dc:creator>
<dc:creator>Ruiz, M</dc:creator>
<dc:creator>Rodríguez, J. C</dc:creator>
<dc:creator>Royo, G</dc:creator>
<dc:creator>Escribano, I</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Después de generar in vitro mutantes de Salmonella spp. con sensibilidad disminuida a las fluoroquinolonas tras su exposición repetida a    concentraciones subinhibitorias de estos fármacos y caracterizar las alteraciones del gen gyrA, hemos determinado la modificación de la actividad    bactericida que presenta el ciprofloxacino sobre los mutantes obtenidos. La pérdida de la actividad bactericida del ciprofloxacino se    detecta en todos los mutantes, pero es mayor en los provenientes de cepas resistentes al ácido nalidíxico. Esto puede ayudar a explicar los    fracasos terapéuticos observados con algunos tratamientos con fluoroquinolonas frente a este tipo de cepas. Además, nuestro modelo    evalúa las primeras interacciones que se producen entre el microorganismo y los antibióticos, y pone de manifiesto que la pérdida de actividad    bactericida del ciprofloxacino es un proceso que se produce tras la exposición a cualquiera de las fluoroquinolonas probadas</dc:description>
<dc:source>Rev Esp Quimioter;19(4): 363-366, dic.2006. tab</dc:source>
<dc:identifier>ibc-053438</dc:identifier>
<dc:title xml:lang="es">Disminución de la actividad bactericida del ciprofloxacino en mutantes de Salmonella generados tras exposición repetida a diversas fluoroquinolonas</dc:title>
<dc:subject>^d36090^s22031</dc:subject>
<dc:subject>^d36090^s22033</dc:subject>
<dc:subject>^d22164^s22033</dc:subject>
<dc:subject>^d4365</dc:subject>
<dc:subject>^d22164^s22031</dc:subject>
<dc:subject>^d12854^s22021</dc:subject>
<dc:subject>^d12863^s22033</dc:subject>
<dc:subject>^d12854^s22033</dc:subject>
<dc:subject>^d12863^s22021</dc:subject>
<dc:subject>^d24248^s22078</dc:subject>
<dc:subject>^d24008^s22078</dc:subject>
<dc:subject>^d36089^s22033</dc:subject>
<dc:subject>^d36089^s22031</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d1449^s22031</dc:subject>
<dc:subject>^d12852^s22033</dc:subject>
<dc:subject>^d12852^s22021</dc:subject>
<dc:subject>^d13025</dc:subject>
<dc:subject>^d1449^s22033</dc:subject>
<dc:subject>^d36060^s22078</dc:subject>
<dc:type>article</dc:type>
<dc:date>200612</dc:date>
</metadata>
</record>
</ibecs-document>
